Paul Covington

Summary

Publications

  1. pmc Randomized, double-blind, phase II, multicenter study evaluating the safety/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infection
    Paul Covington
    Furiex Pharmaceuticals Inc, 3900 Paramount Parkway, Suite 150, Morrisville, North Carolina 27560, USA
    Antimicrob Agents Chemother 55:5790-7. 2011

Detail Information

Publications1

  1. pmc Randomized, double-blind, phase II, multicenter study evaluating the safety/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infection
    Paul Covington
    Furiex Pharmaceuticals Inc, 3900 Paramount Parkway, Suite 150, Morrisville, North Carolina 27560, USA
    Antimicrob Agents Chemother 55:5790-7. 2011
    ..e., lack of spread of lesions and absence of fever at 48 to 72 h), and (ii) cure rates for ABSSSI pathogens (especially MRSA) consistent with the historical literature...